Skip to main content
Austin Angelidakis, Nurse Practitioner, San Francisco, CA, UCSF Medical Center at Mission Bay

AustinAngelidakisNP(He/Him)

Nurse Practitioner • San Francisco, CA

Hematology/Oncology

Nurse Practitioner

Join to view full profile

Austin Angelidakis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Austin Angelidakis' full profile

Already have an account?

Summary

  • Medical oncology, clinical research, primary care

Hospital Affiliations

Education & Training

  • University of Pennsylvania
    University of PennsylvaniaMasters, 2019 - 2021
  • University of Pennsylvania
    University of Pennsylvania Masters, 2017 - 2021
  • University of Pennsylvania
    University of PennsylvaniaBSN, Summa Cum Laude, 2017 - 2018
  • Johns Hopkins University
    Johns Hopkins UniversityPostbaccalaureate studies, Health sciences, 2016 - 2017
  • University of California, Irvine
    University of California, IrvineBS, Biological Sciences, Cum Laude, 2009 - 2013

Publications & Presentations

Abstracts/Posters

  • A phase II study of ZEN-3694 (ZEN), enzalutamide (ENZ), and pembrolizumab (P) in metastatic castration resistant prostate cancer (mCRPC): Interim safety results.
    Jindal, T., Han, H., Deshmukh, P. S., De Kouchkovsky, I., Kwon, D., Borno, H. T., Koshkin, V. S., Desai, A., Bose, R., Chou, J., Friedlander, T., Small, E. J., Angelid..., European Society for Medical Oncology, Paris, France, 9/1/2022
  • A phase Ib study of a single priming dose of 177Lu-PSMA-617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)
    Aggarwal, R., Trihy, L., Hernandez Romero, E., Luch Sam, S., Rastogi, M., De Kouchkovsky, I., Small, E. J., Feng, F., Kwon, D., Friedlander, T., Borno, H. T., Bose, R...., European Society for Medical Oncology, Paris, France, 9/1/2022
  • Long term follow up (LTFU) of adjuvant zoledronic acid (ZOL) in high risk early stage breast cancer (ESBC) defined by bone marrow (BM) disseminated tumor cells (DTC).
    Neelima Vidula, Jimmy Hwang, Sally Greenberg, Michelle E. Melisko, Andrei Goga, Mark Moasser, Ariadna Gasol Cudos, Austin Nicholas Angelidakis, Amy DeLuca, Laura A Pet..., American Society of Clinical Oncology, Chicago, Illinois, 5/30/2017
  • Join now to see all

Other Languages

  • French

External Links

  • LinkedInhttp://www.linkedin.com/in/austinangelidakis